The AIM and EDA Concepts: Why They Are Needed and How They Fit Together - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 128

2. Mitchell JP (2003) Regarding the development and practice of cascade impaction testing,
including a mass balance failure investigation tree. J Aerosol Med 16(4):443
3. Zanen P, Go LT, Lammers JWJ (1994) The optimal particle size for beta-adrenergic aerosols
in mild asthmatics. Int J Pharm 107(3):211-217
4. Zanen P, Go LT, Lammers JWJ (1995) The optimal particle size for parasympathicolytic aero-
sols in mild asthmatics. Int J Pharm 114(1):111-115
5. Zanen P, Go LT, Lammers JWT (1996) Optimal particle size for beta-agonist and anticholiner-
gic aerosols in patients with severe airfl ow limitation. Thorax 51(10):977-980
6. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ (2003) Effects of
bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol
95(5):2106-2112
7. Usmani OS, Biddiscombe MF, Barnes PJ (2005) Regional lung deposition and bronchodilator
response as a function of beta-2 agonist particle size. Am J Respir Crit Care Med
172(12):1497-1504
8. Roland NJ, Bhalla RK, Earis J (2004) The local side effects of inhaled corticosteroids: current
understanding and review of the literature. Chest 126(1):213-219
9. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, Huiart L (2001) Local side
effects of inhaled corticosteroids in asthmatic children: infl uence of drug, dose, age and device.
Allergy 56(10):944-948
10. Laube B, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, Everard ML, Horvath
I, Navalesi P, Voshaar T, Chrystyn H (2011) What the pulmonary specialist should know about
the new inhalation therapies. Eur Respir J 37(6):1308-1331
11. Hallworth GW, Westmoreland DG (1987) The twin impinger: a simple device for assessing the
delivery of drugs from metered dose pressurized aerosol inhalers. J Pharm Pharmacol
39(12):966-972
12. Vidgren M, Silvasti M, Vidgren P, Sormunen H, Laurikaininen K, Korhonen P (1995)
Easyhaler® multiple dose powder inhaler: practical and effective alternative to the pressurized
MDI. Aerosol Sci Technol 22(4):335-345
13. Geuns ERM, Toren JS, Barends DM, Bult A (1997) Decrease of the stage-2 deposition in the
twin impinger during storage of beclomethasone dipropionate dry powder inhalers in con-
trolled and uncontrolled humidities. Eur J Pharm Biopharm 44(2):187-194
14. Miller NC, Marple VA, Schultz RK, Poon WS (1992) Assessment of the twin impinger for size
measurement of metered-dose inhaler sprays. Pharm Res 9(9):1123-1127
15. Van Oort M, Roberts W (1996) Variable fl ow-variable stage-variable volume strategy for cas-
cade impaction testing of inhalation aerosols. In: Dalby RN, Byron PR, Farr SJ (eds)
Respiratory drug delivery V. Interpharm, Buffalo Grove, IL, pp 418-420
16. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd
MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor (a new impac-
tor for pharmaceutical inhaler testing) - Part 1: Design. J Aerosol Med 16(3):283-299
17. Mitchell JP, Dunbar C (2005) The interpretation of data from cascade impactors. J Aerosol
Med 18(4):439-451
18. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S
(2009) Improved quality control metrics for cascade impaction measurements of orally inhaled
drug products (OIPs). AAPS PharmSciTech 10(4):1276-1285
19. European Directorate for the Quality of Medicines and Healthcare (EDQM) (2012)
Preparations for inhalation: aerodynamic assessment of fi ne particles. Section 2.9.18 - European
Pharmacopeia [Apparatus B in versions up to 4th Edn. 2002], Council of Europe, Strasbourg,
France
20. Christopher D, Dey M (2011) Detecting differences in APSD: effi cient data analysis (EDA) vs.
stage grouping. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory
drug delivery Europe 2011. Davis Healthcare International, River Grove, IL, pp 215-224
21. Yu L (2006) Implementation of quality-by-design: OGD initiatives, FDA Advisory Committee
for Pharmaceutical Science Presentation (October 2006). Available at http://www.fda.gov/
ohrms/dockets/ac/06/slides/2006-4241s1_8.ppt . Accessed 10 Jan 2012